Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2M0fvWC
via IFTTT